Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: A randomised cross-over trial. Kearns, N., Bruce, P., Williams, M., Doppen, M., Black, M., Weatherall, M., & Beasley, R. The European Respiratory Journal, February, 2022. doi abstract bibtex OBJECTIVE: To determine the comparative bronchodilator, systemic beta2-agonist, cardiovascular and adverse effects of salbutamol 200 µg and budesonide/formoterol 200/6 µg when taken repeatedly in stable asthma. METHODS: This open-label, cross-over, single-centre, controlled trial, randomised adults with asthma to different orders of two treatment regimens: salbutamol 200 µg via MDI at t=0, 30, 60, 90 min, then salbutamol 2.5 mg via nebuliser at t=120, 140, 160 and 420 min; or budesonide/formoterol 200/6 µg one actuation via Turbuhaler at t=0, 30, 60, 90 min, two actuations at t=120, 140, 160 and 420 min. The primary outcome measure was FEV1 after 180 min. Secondary outcomes included repeat measures of FEV1, serum potassium, heart rate, and adverse events RESULTS: Of 39 patients randomised, two withdrew due to adverse events (QTCF prolongation and T wave abnormalities) after the first intervention with salbutamol. The mean (sd) change from baseline FEV1 180 min after randomisation for salbutamol and budesonide/formoterol regimens was 0.71 (0.46) L, N=38, and 0.58 (0.45) L, N=37, respectively; with a mean (sd) paired difference of -0.10 (0.40) L, N=37, and a model-based estimated difference (95% CI) -0.12 (-0.25 to 0.02) L, p=0.088. In the main secondary analysis, salbutamol resulted in significantly greater FEV1 from 30 to 240 min, but lesser FEV1 at 360 and 420 min. Salbutamol resulted in a significantly lower serum potassium, and a higher heart rate and number of adverse events. CONCLUSION: The comparative bronchodilator responses of repeated administration of salbutamol 200 µg dose-1 and budesonide/formoterol 200/6 µg differed depending on the time of measurement. Salbutamol caused greater systemic beta2-agonist and cardiovascular effects and more adverse events.
@article{kearns_repeated_2022,
title = {Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: {A} randomised cross-over trial},
issn = {1399-3003},
shorttitle = {Repeated dose budesonide/formoterol compared to salbutamol in adult asthma},
doi = {10.1183/13993003.02309-2021},
abstract = {OBJECTIVE: To determine the comparative bronchodilator, systemic beta2-agonist, cardiovascular and adverse effects of salbutamol 200 µg and budesonide/formoterol 200/6 µg when taken repeatedly in stable asthma.
METHODS: This open-label, cross-over, single-centre, controlled trial, randomised adults with asthma to different orders of two treatment regimens: salbutamol 200 µg via MDI at t=0, 30, 60, 90 min, then salbutamol 2.5 mg via nebuliser at t=120, 140, 160 and 420 min; or budesonide/formoterol 200/6 µg one actuation via Turbuhaler at t=0, 30, 60, 90 min, two actuations at t=120, 140, 160 and 420 min. The primary outcome measure was FEV1 after 180 min. Secondary outcomes included repeat measures of FEV1, serum potassium, heart rate, and adverse events RESULTS: Of 39 patients randomised, two withdrew due to adverse events (QTCF prolongation and T wave abnormalities) after the first intervention with salbutamol. The mean (sd) change from baseline FEV1 180 min after randomisation for salbutamol and budesonide/formoterol regimens was 0.71 (0.46) L, N=38, and 0.58 (0.45) L, N=37, respectively; with a mean (sd) paired difference of -0.10 (0.40) L, N=37, and a model-based estimated difference (95\% CI) -0.12 (-0.25 to 0.02) L, p=0.088. In the main secondary analysis, salbutamol resulted in significantly greater FEV1 from 30 to 240 min, but lesser FEV1 at 360 and 420 min. Salbutamol resulted in a significantly lower serum potassium, and a higher heart rate and number of adverse events.
CONCLUSION: The comparative bronchodilator responses of repeated administration of salbutamol 200 µg dose-1 and budesonide/formoterol 200/6 µg differed depending on the time of measurement. Salbutamol caused greater systemic beta2-agonist and cardiovascular effects and more adverse events.},
language = {eng},
journal = {The European Respiratory Journal},
author = {Kearns, Nethmi and Bruce, Pepa and Williams, Mathew and Doppen, Marjan and Black, Melissa and Weatherall, Mark and Beasley, Richard},
month = feb,
year = {2022},
pmid = {35115339},
pages = {2102309},
}
Downloads: 0
{"_id":"wZHJhqy4tHvcbsCAW","bibbaseid":"kearns-bruce-williams-doppen-black-weatherall-beasley-repeateddosebudesonideformoterolcomparedtosalbutamolinadultasthmaarandomisedcrossovertrial-2022","author_short":["Kearns, N.","Bruce, P.","Williams, M.","Doppen, M.","Black, M.","Weatherall, M.","Beasley, R."],"bibdata":{"bibtype":"article","type":"article","title":"Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: A randomised cross-over trial","issn":"1399-3003","shorttitle":"Repeated dose budesonide/formoterol compared to salbutamol in adult asthma","doi":"10.1183/13993003.02309-2021","abstract":"OBJECTIVE: To determine the comparative bronchodilator, systemic beta2-agonist, cardiovascular and adverse effects of salbutamol 200 µg and budesonide/formoterol 200/6 µg when taken repeatedly in stable asthma. METHODS: This open-label, cross-over, single-centre, controlled trial, randomised adults with asthma to different orders of two treatment regimens: salbutamol 200 µg via MDI at t=0, 30, 60, 90 min, then salbutamol 2.5 mg via nebuliser at t=120, 140, 160 and 420 min; or budesonide/formoterol 200/6 µg one actuation via Turbuhaler at t=0, 30, 60, 90 min, two actuations at t=120, 140, 160 and 420 min. The primary outcome measure was FEV1 after 180 min. Secondary outcomes included repeat measures of FEV1, serum potassium, heart rate, and adverse events RESULTS: Of 39 patients randomised, two withdrew due to adverse events (QTCF prolongation and T wave abnormalities) after the first intervention with salbutamol. The mean (sd) change from baseline FEV1 180 min after randomisation for salbutamol and budesonide/formoterol regimens was 0.71 (0.46) L, N=38, and 0.58 (0.45) L, N=37, respectively; with a mean (sd) paired difference of -0.10 (0.40) L, N=37, and a model-based estimated difference (95% CI) -0.12 (-0.25 to 0.02) L, p=0.088. In the main secondary analysis, salbutamol resulted in significantly greater FEV1 from 30 to 240 min, but lesser FEV1 at 360 and 420 min. Salbutamol resulted in a significantly lower serum potassium, and a higher heart rate and number of adverse events. CONCLUSION: The comparative bronchodilator responses of repeated administration of salbutamol 200 µg dose-1 and budesonide/formoterol 200/6 µg differed depending on the time of measurement. Salbutamol caused greater systemic beta2-agonist and cardiovascular effects and more adverse events.","language":"eng","journal":"The European Respiratory Journal","author":[{"propositions":[],"lastnames":["Kearns"],"firstnames":["Nethmi"],"suffixes":[]},{"propositions":[],"lastnames":["Bruce"],"firstnames":["Pepa"],"suffixes":[]},{"propositions":[],"lastnames":["Williams"],"firstnames":["Mathew"],"suffixes":[]},{"propositions":[],"lastnames":["Doppen"],"firstnames":["Marjan"],"suffixes":[]},{"propositions":[],"lastnames":["Black"],"firstnames":["Melissa"],"suffixes":[]},{"propositions":[],"lastnames":["Weatherall"],"firstnames":["Mark"],"suffixes":[]},{"propositions":[],"lastnames":["Beasley"],"firstnames":["Richard"],"suffixes":[]}],"month":"February","year":"2022","pmid":"35115339","pages":"2102309","bibtex":"@article{kearns_repeated_2022,\n\ttitle = {Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: {A} randomised cross-over trial},\n\tissn = {1399-3003},\n\tshorttitle = {Repeated dose budesonide/formoterol compared to salbutamol in adult asthma},\n\tdoi = {10.1183/13993003.02309-2021},\n\tabstract = {OBJECTIVE: To determine the comparative bronchodilator, systemic beta2-agonist, cardiovascular and adverse effects of salbutamol 200 µg and budesonide/formoterol 200/6 µg when taken repeatedly in stable asthma.\nMETHODS: This open-label, cross-over, single-centre, controlled trial, randomised adults with asthma to different orders of two treatment regimens: salbutamol 200 µg via MDI at t=0, 30, 60, 90 min, then salbutamol 2.5 mg via nebuliser at t=120, 140, 160 and 420 min; or budesonide/formoterol 200/6 µg one actuation via Turbuhaler at t=0, 30, 60, 90 min, two actuations at t=120, 140, 160 and 420 min. The primary outcome measure was FEV1 after 180 min. Secondary outcomes included repeat measures of FEV1, serum potassium, heart rate, and adverse events RESULTS: Of 39 patients randomised, two withdrew due to adverse events (QTCF prolongation and T wave abnormalities) after the first intervention with salbutamol. The mean (sd) change from baseline FEV1 180 min after randomisation for salbutamol and budesonide/formoterol regimens was 0.71 (0.46) L, N=38, and 0.58 (0.45) L, N=37, respectively; with a mean (sd) paired difference of -0.10 (0.40) L, N=37, and a model-based estimated difference (95\\% CI) -0.12 (-0.25 to 0.02) L, p=0.088. In the main secondary analysis, salbutamol resulted in significantly greater FEV1 from 30 to 240 min, but lesser FEV1 at 360 and 420 min. Salbutamol resulted in a significantly lower serum potassium, and a higher heart rate and number of adverse events.\nCONCLUSION: The comparative bronchodilator responses of repeated administration of salbutamol 200 µg dose-1 and budesonide/formoterol 200/6 µg differed depending on the time of measurement. Salbutamol caused greater systemic beta2-agonist and cardiovascular effects and more adverse events.},\n\tlanguage = {eng},\n\tjournal = {The European Respiratory Journal},\n\tauthor = {Kearns, Nethmi and Bruce, Pepa and Williams, Mathew and Doppen, Marjan and Black, Melissa and Weatherall, Mark and Beasley, Richard},\n\tmonth = feb,\n\tyear = {2022},\n\tpmid = {35115339},\n\tpages = {2102309},\n}\n\n","author_short":["Kearns, N.","Bruce, P.","Williams, M.","Doppen, M.","Black, M.","Weatherall, M.","Beasley, R."],"key":"kearns_repeated_2022","id":"kearns_repeated_2022","bibbaseid":"kearns-bruce-williams-doppen-black-weatherall-beasley-repeateddosebudesonideformoterolcomparedtosalbutamolinadultasthmaarandomisedcrossovertrial-2022","role":"author","urls":{},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/users/6607533/collections/VKGURBGN/items?key=hSjrOPQRRHHWY81SKs6CEz45&format=bibtex&limit=100","dataSources":["zpWcq5jS35za3AmLx","upP78A3qvEd6tbHFm"],"keywords":[],"search_terms":["repeated","dose","budesonide","formoterol","compared","salbutamol","adult","asthma","randomised","cross","over","trial","kearns","bruce","williams","doppen","black","weatherall","beasley"],"title":"Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: A randomised cross-over trial","year":2022}